Clinical Trial Update: VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating VEGF Trap-Eye for choroidal neovascularization due to pathologic myopia has completed, with results posted in 2014. The product studied…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Pathologic Myopia

Drugs mentioned

• VEGF Trap-Eye (aflibercept) (aflibercept)

Snippet

Sponsor: Bayer | Conditions: Myopia, Pathological | Phase 3 | Status: COMPLETED | Results posted: 2014-04-01